Skip to main content
. 2016 Nov 7;7(49):81645–81660. doi: 10.18632/oncotarget.13162

Figure 5. ERK1/2 is required for the AREG-induced up-regulation of SPRY2.

Figure 5

A and B. SKOV3 cells were pre-treated with vehicle control (DMSO), 10 μM U0126 or 10 μM LY294002 for 1 h and then treated with vehicle control (Ctrl) or 10 ng/mL AREG (AR) for 3 h. The mRNA (A) and protein (B) levels of SPRY2 were examined by RT-qPCR and Western blot, respectively. C and D. SKOV3 (C) and OVCAR5 (D) cells were transfected with 50 nM control siRNA (si-Ctrl) or ERK1/2 siRNAs (si-ERK1/2) for 48 h and then treated with vehicle control (Ctrl) or 10 ng/mL AREG (AR) for 3 h. The protein levels of SPRY2 and ERK1/2 were examined by Western blot. The results are presented as the mean ± SEM of at least three independent experiments. Values without a common letter are significantly different (P < 0.05).